- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00003145
Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte Infusion in Treating Older Patients With Chronic Myeloid Leukemia
Induction of Mixed Hematopoietic Chimerism Using Fludarabine, Low Dose TBI , PBSC Infusion and Post-Transplant Immunosuppression With Cyclosporine and Mycophenolate Mofetil to be Followed by Donor Lymphocyte Infusion In Patients With Chronic Myeloid Leukemia in Chronic and Accelerated Phases: A Multi-center Study
Study Overview
Status
Conditions
Intervention / Treatment
- Other: Laboratory Biomarker Analysis
- Radiation: Total-Body Irradiation
- Drug: Fludarabine Phosphate
- Drug: Mycophenolate Mofetil
- Procedure: Peripheral Blood Stem Cell Transplantation
- Drug: Cyclosporine
- Biological: Therapeutic Allogeneic Lymphocytes
- Procedure: Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation
Detailed Description
PRIMARY OBJECTIVES:
I. To determine if mixed hematopoietic chimerism can be safely established using a non-myeloablative conditioning regimen in patients > 65 years of age with chronic myeloid leukemia (CML) in chronic or accelerated phase who have human leukocyte antigen (HLA) identical related donors.
II. To determine if mixed chimerism, established with non-myeloablative conditioning regimens, can be converted to full donor hematopoietic chimerism by infusions of donor lymphocytes (DLI), and thereby produce an immunologic cure of the malignancy.
OUTLINE:
CONDITIONING REGIMEN: Patients receive fludarabine phosphate intravenously (IV) on days -4 to -2 and undergo low-dose total-body irradiation (TBI) on day 0.
TRANSPLANTATION: Patients undergo allogeneic peripheral blood stem cell transplantation (PBSCT) on day 0.
IMMUNOSUPPRESSION: Patients receive cyclosporine orally (PO) twice daily (BID) or IV BID or thrice daily (TID) on days -3 to 56 with taper to day 77 or 180, and mycophenolate mofetil PO or IV BID on days 0-27.
DLI: At least 2 weeks after completion of immunosuppression, patients with > 5% donor cluster of differentiation (CD)3+ T cells and no evidence of graft-versus-host disease (GVHD) receive donor lymphocytes IV over 30 minutes. Patients may receive up to 3 DLIs at increasing cell doses in the absence of GVHD.
After completion of study treatment, patients are followed up periodically for 5 years.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Leipzig, Germany, D-04103
- Universitaet Leipzig
-
-
-
-
-
Torino, Italy, 10126
- University of Torino
-
-
-
-
California
-
Duarte, California, United States, 91010
- City of Hope Medical Center
-
Stanford, California, United States, 94305
- Stanford University Hospitals and Clinics
-
-
Colorado
-
Denver, Colorado, United States, 80217-3364
- University of Colorado
-
-
Texas
-
Dallas, Texas, United States, 75246
- Baylor University Medical Center
-
-
Washington
-
Seattle, Washington, United States, 98109
- Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
-
Seattle, Washington, United States, 98101
- VA Puget Sound Health Care System
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients with Philadelphia chromosome positive (Ph+) CML in first and second chronic and first accelerated phases
- Patients =< 65 years old who are at high risk of regimen related toxicity through pre-existing chronic disease affecting liver, lungs, and/or heart, or others who wish to be treated on this protocol, will be considered on a case-by-case basis; transplants should be approved for these inclusion criteria by both the participating institutions' patient review committees such as the Patient Care Conference (PCC) at the Fred Hutchinson Cancer Research Center (FHCRC) and by the principal investigators at the collaborating centers; patients =< 65 years of age who have received previous high-dose transplantation do not require patient review committee approvals; all children < 12 years must be discussed with the FHCRC principal investigator (PI) (Brenda Sandmaier, MD 206-667-4961) prior to registration
- HLA genotypically identical related donor willing to undergo leukapheresis initially for collection of peripheral blood stem cell (PBSC) and subsequently for collection of peripheral blood mononuclear cell (PBMC)
- Patients treated with alpha interferon must have discontinued drug at least 1 month prior to transplant
- DONOR: HLA genotypically identical family member (excluding identical twins)
- DONOR: Donor must consent to filgrastim (G-CSF) administration and leukapheresis
- DONOR: Donor must have adequate veins for leukapheresis or agree to placement of central venous catheter (femoral, subclavian)
Exclusion Criteria:
- Patients who are human immunodeficiency virus positive (HIV+)
- GROUP 1: (PATIENTS AGED > 65 AND < 75 YEARS)
- Patients unwilling to use contraceptive techniques during and for 12 months following treatment
- Presence of circulating leukemic blasts (in the peripheral blood) detected by standard pathology for patients with CML
- Patients in an interferon induced complete or partial cytogenetic remission
Organ dysfunction:
- Patients with renal failure are eligible, however patients with renal compromise (Serum creatinine greater than 2.0) will likely have further compromise in renal function and may require hemodialysis (which may be permanent) due to the need to maintain adequate serum cyclosporine levels
- Cardiac ejection fraction < 40%; ejection fraction is required if the patient has a history of anthracyclines or history of cardiac disease
- Diffusing capacity of the lung for carbon monoxide (DLCO) < 50% of predicted
- Liver function tests including total bilirubin, serum glutamic pyruvate transaminase (SGPT) and serum glutamic oxaloacetic transaminase (SGOT) > 2x the upper limit of normal unless proven to be due to the malignancy
- Karnofsky score < 70
- Patients with poorly controlled hypertension
- GROUP 2 (PATIENTS AGED =< 65)
- Patients who are HIV+
- Presence of circulating leukemic blasts (in the peripheral blood) detected by standard pathology for patients with CML
- Females who are pregnant
- Patients unwilling to use contraceptive techniques during and for 12 months following treatment
- Patients in an interferon induced complete or partial cytogenetic remission
Organ dysfunction:
- Patients with renal failure are eligible, however patients with renal compromise (Serum creatinine greater than 2.0) will likely have further compromise in renal function and may require hemodialysis (which may be permanent) due to the need to maintain adequate serum cyclosporine levels
- Cardiac ejection fraction < 40% or a history of congestive heart failure; ejection fraction is required if the patient has a history of anthracyclines or history of cardiac disease
- Severe defects in pulmonary function testing as defined by the pulmonary consultant (defects are currently categorized as mild, moderate and severe) or receiving supplementary continuous oxygen; DLCO < 50% of predicted
- Liver function tests: total bilirubin > 2x the upper limit of normal, SGPT and SGOT 4x the upper limit of normal
- Karnofsky score < 50
- Patients with poorly controlled hypertension
- DONOR: Age less than 12 years
- DONOR: Pregnancy
- DONOR: Infection with HIV
- DONOR: Inability to achieve adequate venous access
- DONOR: Known allergy to G-CSF
- DONOR: Current serious systemic illness
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment (chemotherapy, TBI, PBSCT, DLI)
CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV on days -4 to -2 and undergo low-dose TBI on day 0. TRANSPLANTATION: Patients undergo allogeneic PBSCT on day 0. IMMUNOSUPPRESSION: Patients receive cyclosporine PO BID or IV BID or TID on days -3 to 56 with taper to day 77 or 180, and mycophenolate mofetil PO or IV BID on days 0-27. DLI: At least 2 weeks after completion of immunosuppression, patients with > 5% donor CD3+ T cells and no evidence of GVHD receive donor lymphocytes IV over 30 minutes. Patients may receive up to 3 DLIs at increasing cell doses in the absence of GVHD. |
Correlative studies
Undergo TBI
Other Names:
Given IV
Other Names:
Given PO or IV
Other Names:
Undergo allogeneic PBSCT
Other Names:
Given PO or IV
Other Names:
Given IV
Other Names:
Undergo allogeneic PBSCT
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety of establishing mixed chimerism using this non-lethal conditioning regimen, in terms of development of GVHD, myelosuppression, infections, and treatment-related mortality
Time Frame: Within the first 65 days
|
All unexpected toxicities will be summarized and reported.
|
Within the first 65 days
|
Proportion of patients who successfully establish mixed chimerism (evidence of donor engraftment) and the proportion who convert to full donor chimeras among those who were mixed
Time Frame: Day 28
|
Estimated and corresponding confidence intervals presented.
Mixed chimerism is detection of donor T cells (CD3+) and granulocytes (CD33+), as proportion of total T cell and granulocyte population of > 5% and < 95% in peripheral blood.
Full donor chimerism is > 95% donor CD3+ T cells.
Increasing donor chimerism is absolute increase of 20% of CD3+ T cells over chimerism evaluation of previous month.
Decreasing donor chimerism is absolute decrease of 20% of CD3+ T cell chimerism over previous month.
Low donor chimerism is < 40% CD3+ T cells after HSCT.
|
Day 28
|
Proportion of patients who successfully establish mixed chimerism (evidence of donor engraftment) and the proportion who convert to full donor chimeras among those who were mixed
Time Frame: Day 56
|
Estimated and corresponding confidence intervals presented.
Mixed chimerism is detection of donor T cells (CD3+) and granulocytes (CD33+), as proportion of total T cell and granulocyte population of > 5% and < 95% in peripheral blood.
Full donor chimerism is > 95% donor CD3+ T cells.
Increasing donor chimerism is absolute increase of 20% of CD3+ T cells over chimerism evaluation of previous month.
Decreasing donor chimerism is absolute decrease of 20% of CD3+ T cell chimerism over previous month.
Low donor chimerism is < 40% CD3+ T cells after HSCT.
|
Day 56
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of patients experiencing a complete antileukemic response
Time Frame: At 12 weeks after the final DLI
|
Reported in a descriptive manner and confidence intervals will be presented for all estimates.
|
At 12 weeks after the final DLI
|
Proportion of patients experiencing GVHD
Time Frame: Until day 90 after the last DLI
|
Reported in a descriptive manner and confidence intervals will be presented for all estimates.
|
Until day 90 after the last DLI
|
Proportion of patients experiencing non-relapse mortality
Time Frame: Within 65 days of transplant
|
Reported in a descriptive manner and confidence intervals will be presented for all estimates.
|
Within 65 days of transplant
|
Incidence of myelosuppression after initial PBSC infusion
Time Frame: Until 2 months post-transplant
|
Defined as absolute neutrophil count [ANC] < 500 for > 2 days, platelets < 20,000 for > 2 days.
|
Until 2 months post-transplant
|
Incidence of aplasia after DLI
Time Frame: Until 2 months post-transplant
|
Until 2 months post-transplant
|
|
Incidence of grades 2-4 acute GVHD after DLI
Time Frame: Until day 90 after the last DLI
|
Until day 90 after the last DLI
|
|
Incidence of grades 2-4 acute GVHD after PBSC infusion
Time Frame: Until day 90 after the last DLI
|
Until day 90 after the last DLI
|
|
Incidence of grade chronic extensive GVHD after DLI
Time Frame: At 1 year
|
At 1 year
|
|
Dose of CD3+ cells required to convert mixed to full lymphoid chimeras
Time Frame: Day 56
|
Day 56
|
Collaborators and Investigators
Sponsor
Collaborators
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Bone Marrow Diseases
- Hematologic Diseases
- Myeloproliferative Disorders
- Leukemia
- Leukemia, Myeloid
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Enzyme Inhibitors
- Antirheumatic Agents
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Dermatologic Agents
- Anti-Bacterial Agents
- Antibiotics, Antineoplastic
- Antifungal Agents
- Antitubercular Agents
- Antibiotics, Antitubercular
- Calcineurin Inhibitors
- Fludarabine
- Fludarabine phosphate
- Mycophenolic Acid
- Cyclosporine
- Cyclosporins
Other Study ID Numbers
- 1209.00 (Other Identifier: Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium)
- P30CA015704 (U.S. NIH Grant/Contract)
- NCI-2012-00579 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Recurrent Disease
-
Steven BurtonCompletedRecurrent Oligometastatic DiseaseUnited States
-
Mehdi YousefiCompletedRecurrent Implantation FailureIran, Islamic Republic of
-
Centre Hospitalier Universitaire, AmiensCompleted
-
Kasr El Aini HospitalUnknownRecurrent Implantation Failure
-
Sohag UniversityRecruitingRecurrent WheezesEgypt
-
Dr. Kamal RagehCompleted
-
SCARM Institute, Tabriz, IranCompleted
-
Cairo UniversityCompleted
-
Tabriz University of Medical SciencesCompletedRecurrent Implantation FailureIran, Islamic Republic of
-
Shanghai First Maternity and Infant HospitalUnknownRecurrent Implantation FailureChina
Clinical Trials on Laboratory Biomarker Analysis
-
Children's Oncology GroupNational Cancer Institute (NCI)Completed
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Active, not recruitingLeukemia | Acute Lymphoblastic Leukemia | Acute Promyelocytic LeukemiaUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedUntreated Adult Acute Lymphoblastic Leukemia | Untreated Childhood Acute Lymphoblastic LeukemiaUnited States, Canada, Australia, New Zealand, Puerto Rico, Switzerland
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedChildhood Acute Lymphoblastic Leukemia in Remission | Recurrent Childhood Acute Lymphoblastic LeukemiaUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)CompletedLung CancerUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Completed
-
Children's Oncology GroupNational Cancer Institute (NCI)WithdrawnClear Cell Renal Cell Carcinoma | Rhabdoid Tumor of the Kidney | Congenital Mesoblastic Nephroma | Childhood Kidney NeoplasmUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)WithdrawnBreast Carcinoma | BRCA1 Mutation Carrier | BRCA2 Mutation CarrierUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedWilms Tumor and Other Childhood Kidney TumorsUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedChildhood Acute Monoblastic Leukemia (M5a) | Childhood Acute Monocytic Leukemia (M5b) | Childhood Acute Myeloblastic Leukemia Without Maturation (M1) | Childhood Acute Myelomonocytic Leukemia (M4) | Childhood Acute Myeloid Leukemia/Other Myeloid MalignanciesUnited States